The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share ...
Savara Inc (SVRA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices ...
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, with MOLBREEVI targeting autoimmune PAP. SVRA's cash runway extends into H2 2027, bolstered by $203M in ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...
Savara Inc. is a biotech company focused on rare lung diseases that joined the Nasdaq in 2017. Today, management shared the news that lead candidate, molgramostim met primary and secondary endpoints ...
Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry ...
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results